Stock Taper
NRSNW
NEUROSENSE THERAPEUTICS LTD.
NASDAQ
$0.05
▲ UP 9.65% (0.00)

KEY STATISTICS

Market Cap$1.23 M
52w High$0.30
52w Low$0.05
Dividend Yield
Frequency
P/E-0.10
Volume7
Shares Out.24.67M

COMPANY

LEADERSHIP

Alon Ben-Noon
CHIEF EXECUTIVE
Alon Ben-Noon

ABOUT

SECTOR
Healthcare
WENT PUBLIC
December 9, 2021
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
16

UPCOMING EARNINGS

DateDec 2, 2026
DayWednesday
Rev. Est.$535.60K
DEC
2
WED

PRICE

$0.05 ▲ UP 9.65% (+$0.00)
$0.04$0.05$0.051:20 PM1:20 PM1:20 PM1:20 PM1:20 PM1:20 PM1:21 PM0.05

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com ↗

NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotech developing treatments for neurodegenerative diseases, with lead candidate PrimeC for ALS and pipeline candidates for Parkinson’s and Alzheimer’s.

INDUSTRY

Biotechnology

A PRODUCT NEUROSENSE THERAPEUTICS LTD. IS KNOWN FOR

PrimeC
PrimeC

PrimeC, NeuroSense's oral fixed-dose combo of ciprofloxacin and celecoxib for ALS, has FDA and EMA Orphan Drug Designation and is preparing for Phase 3 after positive Phase 2b results.

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
Purchase · 250.0K shares
2026-06-16
OFFICER: CHIEF EXECUTIVE OFFICER
Ben-Noon Alon
Purchase · 250.0K shares
2026-06-16
OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
Purchase · 200.0K shares
2026-03-26
OFFICER: CHIEF FINANCIAL OFFICER
Eisenberg Or
· 21.0K shares
2021-07-01

SECTORS PEERS

PEERPRICE
BCLI$1.06COMPARE
APRE$0.80COMPARE
ADIL$6.89COMPARE
ACXP$1.40COMPARE
CDIO$1.80COMPARE
ADXN$3.72COMPARE
CELZ$1.09COMPARE
HCWB$2.92COMPARE